Insmed’s Brensocatib Enters Trial as Possible COVID-19 Treatment

Insmed is sponsoring a clinical trial in the UK of its bronchial drug Brensocatib as a potential  COVID-19 treatment.

Designated urgent by the UK's National Institute for Health Research, the trial will include up to 300 patients at 10 sites.

Patients enrollment is expected to begin in May.